CA2812759A1 - Methods for diagnosing lyme disease - Google Patents
Methods for diagnosing lyme disease Download PDFInfo
- Publication number
- CA2812759A1 CA2812759A1 CA2812759A CA2812759A CA2812759A1 CA 2812759 A1 CA2812759 A1 CA 2812759A1 CA 2812759 A CA2812759 A CA 2812759A CA 2812759 A CA2812759 A CA 2812759A CA 2812759 A1 CA2812759 A1 CA 2812759A1
- Authority
- CA
- Canada
- Prior art keywords
- antibodies
- burgdorferi
- ospc
- ospf
- ospa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 86
- 238000000034 method Methods 0.000 title claims abstract description 54
- 108700023315 OspC Proteins 0.000 claims abstract description 160
- 241000589969 Borreliella burgdorferi Species 0.000 claims abstract description 151
- 108700006640 OspA Proteins 0.000 claims abstract description 139
- 239000000427 antigen Substances 0.000 claims abstract description 94
- 108091007433 antigens Proteins 0.000 claims abstract description 94
- 102000036639 antigens Human genes 0.000 claims abstract description 94
- 241000124008 Mammalia Species 0.000 claims abstract description 68
- 239000012472 biological sample Substances 0.000 claims abstract description 22
- 230000001684 chronic effect Effects 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 7
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 7
- 238000007837 multiplex assay Methods 0.000 claims description 84
- 239000011324 bead Substances 0.000 claims description 79
- 238000012360 testing method Methods 0.000 claims description 72
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 241000283073 Equus caballus Species 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 7
- 241000589968 Borrelia Species 0.000 claims 1
- 241000283086 Equidae Species 0.000 abstract description 27
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 19
- 238000001262 western blot Methods 0.000 description 119
- 210000002966 serum Anatomy 0.000 description 67
- 238000003556 assay Methods 0.000 description 60
- 238000004458 analytical method Methods 0.000 description 47
- 230000035945 sensitivity Effects 0.000 description 44
- 241000282465 Canis Species 0.000 description 37
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 29
- 238000001514 detection method Methods 0.000 description 22
- 239000000523 sample Substances 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 20
- 239000011159 matrix material Substances 0.000 description 18
- 238000002255 vaccination Methods 0.000 description 17
- 239000012634 fragment Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000010200 validation analysis Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000013459 approach Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 238000013476 bayesian approach Methods 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 239000012130 whole-cell lysate Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000010207 Bayesian analysis Methods 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 102100021941 Sorcin Human genes 0.000 description 3
- 101710089292 Sorcin Proteins 0.000 description 3
- 241000589970 Spirochaetales Species 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001400 expression cloning Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101710151906 31 kDa protein Proteins 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- 108091006054 His-tagged proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 101710106459 29 kDa protein Proteins 0.000 description 1
- 241000908522 Borreliella Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 241000238703 Ixodes scapularis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102100039641 Protein MFI Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000011312 Vector Borne disease Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940099789 ospa protein Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38669410P | 2010-09-27 | 2010-09-27 | |
| US61/386,694 | 2010-09-27 | ||
| PCT/US2011/053359 WO2012047607A2 (en) | 2010-09-27 | 2011-09-27 | Methods for diagnosing lyme disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2812759A1 true CA2812759A1 (en) | 2012-04-12 |
Family
ID=45928310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2812759A Abandoned CA2812759A1 (en) | 2010-09-27 | 2011-09-27 | Methods for diagnosing lyme disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8946393B2 (https=) |
| EP (1) | EP2622346A4 (https=) |
| JP (1) | JP2013539032A (https=) |
| KR (1) | KR20130101067A (https=) |
| CN (1) | CN103229055A (https=) |
| BR (1) | BR112013007329A2 (https=) |
| CA (1) | CA2812759A1 (https=) |
| MX (1) | MX2013003609A (https=) |
| RU (1) | RU2013118647A (https=) |
| WO (1) | WO2012047607A2 (https=) |
| ZA (1) | ZA201302402B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT106942B (pt) | 2013-05-15 | 2020-09-10 | STAB VIDA, Investigação e Serviços em Ciências Biológicas, Lda | Biochip (1) e bouquet de 16 antigénios (2) para a deteção da doença de lyme aguda e crónica |
| EP4108256A1 (en) * | 2014-08-11 | 2022-12-28 | University of Massachusetts | Anti-ospa antibodies and methods of use |
| CN104374921B (zh) * | 2014-11-21 | 2016-09-07 | 安徽医科大学 | 一种用于莱姆病鞭毛抗原免疫血清学诊断的蛋白质芯片及其制备方法和应用 |
| FI3353551T3 (fi) | 2015-09-25 | 2023-01-31 | Koostumuksia ja menetelmiä lymen taudin diagnosoimiseksi ja lymen tautia aiheuttavan spirokeetan eliminaation ennustamiseksi hoidon jälkeen | |
| CN105524989A (zh) * | 2015-12-31 | 2016-04-27 | 中国疾病预防控制中心传染病预防控制所 | 用于检测莱姆病螺旋体的rpa引物和探针及检测方法 |
| CN105628918A (zh) * | 2016-02-04 | 2016-06-01 | 浙江大学 | 一种蜱传莱姆病伯氏疏螺旋体检测试剂及应用 |
| CN113302493A (zh) * | 2018-10-01 | 2021-08-24 | 小利兰·斯坦福大学托管委员会 | 同时解析多种抗体同种型的高特异性和灵敏度免疫吸附诊断测定 |
| EP4088115A1 (en) * | 2020-01-10 | 2022-11-16 | Quidel Corporation | Test strip with structured substrate for multiplex lateral flow assay for disease diagnostics |
| EP4136251A4 (en) * | 2020-04-13 | 2024-10-02 | ID-Fish Technology, Inc. | DETECTION OF LYME DISEASE |
| US20230324382A1 (en) * | 2022-02-01 | 2023-10-12 | Trustees Of Tufts College | Antiphospholipid antibodies for the diagnosis of lyme disease |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US5777095A (en) * | 1988-10-24 | 1998-07-07 | Symbicom Aktiebolag | Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90 |
| US6300101B1 (en) | 1988-10-24 | 2001-10-09 | Board Of Regents, The University Of Texas System | Methods and compositions including a 13kD B. burgdorferi protein |
| US6143872A (en) * | 1988-10-24 | 2000-11-07 | Symbicom Aktiebolag | Borrelia burdorferi Osp A and B proteins and immunogenic peptides |
| US6872550B1 (en) * | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
| US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
| US6248562B1 (en) * | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| US7008625B2 (en) * | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US5620862A (en) | 1993-11-24 | 1997-04-15 | University Of Connecticut | Methods for diagnosing early Lyme disease |
| EP0757556B1 (en) * | 1994-04-11 | 2006-06-14 | Wyeth Holdings Corporation | Borrelia burgdorferi bacterin |
| US5558993A (en) * | 1994-06-17 | 1996-09-24 | The Regents Of The University Of California | Cloned Borrelia burgdorferi virulence protein |
| CZ42497A3 (en) * | 1994-08-17 | 1997-10-15 | Max Planck Gesellschaft | VACCINE CONTAINING BORRELIA BURGDORFERI OspG |
| US5853987A (en) * | 1995-04-24 | 1998-12-29 | The Texas A & M University System | Decorin binding protein compositions and methods of use |
| WO1997015600A1 (en) | 1995-10-26 | 1997-05-01 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Tick (ixodes scapularis) vector saliva-induced lyme disease spirochete (borrelia burgdorferi) antigens as vaccine candidates |
| ATE232212T1 (de) | 1996-05-02 | 2003-02-15 | Dako As | Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden |
| US6716574B2 (en) * | 1996-05-02 | 2004-04-06 | Dako A/S | Osp-C derived peptide fragments |
| US6902893B1 (en) | 1997-06-20 | 2005-06-07 | Gil H. Choi | Lyme disease vaccines |
| DK1012181T3 (da) | 1997-06-30 | 2007-01-02 | Univ Tulane | Overfladeantigener og proteiner, der er nyttige i præparater til diagnose og forebyggelse af Lymes sygdom |
| US6610838B1 (en) * | 1997-09-10 | 2003-08-26 | Symbicom Aktiebolag | P13 antigens from Borrelia |
| PT1100922E (pt) | 1998-07-31 | 2008-05-30 | Gundersen Lutheran Medical Fou | Utilização do(s) epítopo(s) borrelicida(s) da proteína de superfície externa c (ospc) de borrelia burgdorferi, como vacina |
| WO2000018791A1 (en) * | 1998-09-29 | 2000-04-06 | Statens Serum Institut | Ligand presenting assembly (lpa), method of preparation and uses thereof |
| US6475492B1 (en) | 1999-04-28 | 2002-11-05 | The Administrators Of The Tulane Educational Fund | Peptides and assays for the diagnosis of lyme disease |
| WO2000078800A2 (en) * | 1999-06-18 | 2000-12-28 | Medimmune, Inc. | Combined decorin binding protein and outer surface protein compositions and methods of use |
| US20030134345A1 (en) * | 2001-07-17 | 2003-07-17 | Michael Brunner | Serological assay for detection of antigens sequested within immune complexes |
| FI112544B (fi) * | 2001-11-26 | 2003-12-15 | Bortech Oy | Menetelmä varhais- ja myöhäisvaiheen Lymen borrelioosin diagnosoimiseksi |
| US20050058661A1 (en) | 2002-10-18 | 2005-03-17 | Sykes Kathryn F. | Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia |
| US8821893B2 (en) | 2004-07-02 | 2014-09-02 | Bio Peptides, Corp. | Oral vaccine for Borrelia |
| US7390626B2 (en) | 2005-02-25 | 2008-06-24 | Immunosciences Lab., Inc. | Methods and kit for diagnosing tick borne illnesses |
| CN101374858A (zh) * | 2005-11-29 | 2009-02-25 | 弗吉尼亚州立大学 | 多价嵌合ospc疫苗原及诊断抗原 |
| AU2006320246A1 (en) | 2005-11-29 | 2007-06-07 | Virginia Commonwealth University | Polyvalent chimeric OspC vaccinogen and diagnostic antigen |
| WO2007133623A2 (en) | 2006-05-10 | 2007-11-22 | Biopeptides Corporation | Peptide diagnostic agent for lyme disease |
| AU2007295927A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
| US8247181B2 (en) | 2007-09-07 | 2012-08-21 | The Regents Of The University Of California | Borrelia diagnostics and screening methods |
| EP2274616A1 (en) | 2008-04-22 | 2011-01-19 | The Research Foundation of State University of New York | Borrelia burgdorferi cell envelope protein array |
| WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
| US8565892B2 (en) * | 2009-10-31 | 2013-10-22 | Qteris, Inc. | Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment |
| WO2011068844A1 (en) | 2009-12-01 | 2011-06-09 | Temple Douglas | Borrelia burgdorferi bacterial antigen diagnostic test using polymeric bait containing capture particles |
-
2011
- 2011-09-27 RU RU2013118647/15A patent/RU2013118647A/ru not_active Application Discontinuation
- 2011-09-27 US US13/876,077 patent/US8946393B2/en active Active
- 2011-09-27 CA CA2812759A patent/CA2812759A1/en not_active Abandoned
- 2011-09-27 WO PCT/US2011/053359 patent/WO2012047607A2/en not_active Ceased
- 2011-09-27 BR BR112013007329A patent/BR112013007329A2/pt not_active IP Right Cessation
- 2011-09-27 MX MX2013003609A patent/MX2013003609A/es not_active Application Discontinuation
- 2011-09-27 CN CN2011800562501A patent/CN103229055A/zh active Pending
- 2011-09-27 EP EP11831265.1A patent/EP2622346A4/en not_active Withdrawn
- 2011-09-27 JP JP2013530408A patent/JP2013539032A/ja active Pending
- 2011-09-27 KR KR1020137010849A patent/KR20130101067A/ko not_active Withdrawn
-
2013
- 2013-04-03 ZA ZA2013/02402A patent/ZA201302402B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2622346A2 (en) | 2013-08-07 |
| WO2012047607A3 (en) | 2012-08-16 |
| ZA201302402B (en) | 2014-06-25 |
| RU2013118647A (ru) | 2014-11-10 |
| EP2622346A4 (en) | 2014-04-16 |
| MX2013003609A (es) | 2013-10-17 |
| BR112013007329A2 (pt) | 2016-07-19 |
| US8946393B2 (en) | 2015-02-03 |
| US20130273572A1 (en) | 2013-10-17 |
| CN103229055A (zh) | 2013-07-31 |
| KR20130101067A (ko) | 2013-09-12 |
| JP2013539032A (ja) | 2013-10-17 |
| WO2012047607A2 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8946393B2 (en) | Methods for diagnosing lyme disease | |
| Tokarz et al. | A multiplex serologic platform for diagnosis of tick-borne diseases | |
| US20120142023A1 (en) | Proteins and method for detection of lyme disease | |
| US9816991B2 (en) | Diagnostic peptides for lyme disease | |
| Wagner et al. | Development of a multiplex assay for the detection of antibodies to Borrelia burgdorferi in horses and its validation using Bayesian and conventional statistical methods | |
| US7390626B2 (en) | Methods and kit for diagnosing tick borne illnesses | |
| Wagner et al. | A fluorescent bead-based multiplex assay for the simultaneous detection of antibodies to B. burgdorferi outer surface proteins in canine serum | |
| US20180238874A1 (en) | Proteins used for the diagnosis of lyme borreliosis | |
| US9290548B2 (en) | Proteins used for the diagnosis of lyme borreliosis | |
| US20250290925A1 (en) | Method for detecting lyme disease | |
| Pachner et al. | Western blotting in evaluating Lyme seropositivity and the utility of a gel densitometric approach | |
| US20030134345A1 (en) | Serological assay for detection of antigens sequested within immune complexes | |
| US10006912B2 (en) | Peptides for diagnosing lyme disease | |
| JP7489228B2 (ja) | ＳＡＲＳ－ＣｏＶ－２由来ヌクレオカプシド断片および該断片を用いて抗ＳＡＲＳ－ＣｏＶ－２抗体を検出する方法およびキット | |
| Krishnamurthy et al. | A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases | |
| WO2020158811A1 (ja) | ヘリコバクター・ピロリ菌株の同定方法、および同定用キット | |
| WO2018017998A1 (en) | Recombinant borrelia proteins and methods of use thereof | |
| CHOI et al. | CysA2: A candidate serodiagnostic marker for Mycobacterium tuberculosis infection | |
| Noguera et al. | Brucela abortus: Potential Biomarkers for Detecting Exposure to Brucellosis | |
| Escarcega Avila | A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases | |
| Annukka et al. | Clinical performance and analytical accuracy of a C6 peptide-based point-of-care lateral flow immunoassay in Lyme borreliosis serology | |
| US20220349882A1 (en) | Bovine pathogen array |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20160928 |